Targeted Sequencing Market - Strategic Insights and Forecasts (2026-2035)

The Targeted Sequencing market is growing at a CAGR of 10.3% from USD 7.66 billion in 2026 to USD 18.53 billion in 2035.

Targeted sequencing enables selective analysis of predefined genomic regions associated with specific diseases, offering faster, more cost-effective, and clinically actionable insights compared to whole genome sequencing. The technology has become a cornerstone of precision medicine because it provides highly accurate mutation detection while minimizing data complexity and turnaround time. Continuous advances in next-generation sequencing (NGS), target enrichment technologies, artificial intelligence (AI)-assisted variant interpretation, and bioinformatics platforms are expanding targeted sequencing applications across oncology, hereditary disease testing, reproductive health, infectious disease surveillance, and pharmacogenomics.

Market Drivers

Growing Adoption of Biomarker-Guided Therapies

Targeted therapies increasingly require genomic evidence before treatment initiation. As more oncology drugs receive biomarker-based approvals, healthcare providers are expanding targeted sequencing programs to identify clinically actionable mutations and improve treatment selection.

Expansion of Precision Oncology

Cancer management is becoming increasingly dependent on comprehensive molecular profiling. Targeted sequencing enables accurate detection of somatic mutations, gene fusions, copy number variations, and other genomic alterations that support personalized treatment decisions.

Rising Demand for Infectious Disease Surveillance

Healthcare systems are increasingly utilizing targeted sequencing to identify pathogens, monitor antimicrobial resistance, characterize outbreaks, and improve public health surveillance programs.

Increasing Genomic Testing Capacity

Hospitals, diagnostic laboratories, and research institutions continue expanding molecular diagnostic capabilities as precision medicine becomes integrated into routine healthcare. Growing laboratory automation and improved sequencing workflows are supporting higher testing volumes.

Market Restraints

High Initial Investment

Advanced sequencing instruments, laboratory infrastructure, and computational resources require significant capital investment, limiting adoption among smaller healthcare providers.

Complex Bioinformatics Requirements

Accurate variant interpretation requires sophisticated bioinformatics software, standardized analytical pipelines, and experienced genomic specialists, increasing operational complexity.

Regulatory and Clinical Validation

Clinical implementation requires rigorous validation, regulatory compliance, and quality assurance before targeted sequencing assays can be routinely adopted across healthcare systems.

Market and Technology Insights

The global targeted sequencing market can be segmented by product & service, technology, application, end user, and geography.

By product & service, the market includes instruments, consumables & reagents, sequencing services, and bioinformatics & data analysis services. Consumables and reagents account for a significant share because of recurring demand throughout sequencing workflows, while bioinformatics services continue expanding alongside increasing sequencing volumes.

By technology, the market comprises amplicon-based sequencing and hybridization capture-based sequencing. Amplicon-based sequencing remains widely adopted for rapid mutation analysis because it provides high sensitivity and cost efficiency, while hybridization capture technologies are increasingly utilized for comprehensive genomic profiling and larger gene panels.

By application, the market includes oncology, hereditary disease testing, reproductive health testing, infectious disease testing, and pharmacogenomics. Oncology represents the largest application segment because targeted therapies increasingly depend on genomic evidence for treatment selection. Hereditary disease testing and pharmacogenomics continue experiencing significant growth as precision medicine expands across multiple therapeutic areas.

By end user, the market serves hospitals & diagnostic laboratories, academic & research institutes, and pharmaceutical & biotechnology companies. Hospitals and diagnostic laboratories continue expanding genomic testing capabilities to meet growing clinical demand, while pharmaceutical companies increasingly utilize targeted sequencing for biomarker discovery and companion diagnostic development.

Market Trends

The targeted sequencing market continues evolving through technological innovation.

Key trends include:

• Increasing adoption of disease-specific sequencing panels.
• Expansion of companion diagnostics.
• Growing integration of artificial intelligence into variant interpretation.
• Higher laboratory automation.
• Expansion of precision oncology programs.
• Increasing utilization of targeted sequencing in pharmacogenomics.
• Development of integrated sequencing and reporting platforms.

Regional Insights

North America remains the largest market because precision medicine adoption increasingly influences clinical decision-making. Healthcare providers continue expanding genomic testing programs, while pharmaceutical companies accelerate biomarker-driven drug development. Investment in laboratory automation, integrated bioinformatics platforms, and companion diagnostics continues strengthening regional market growth.

Europe maintains a significant market share through expanding genomic medicine programs, increasing implementation of personalized healthcare, and growing adoption of targeted sequencing across academic and clinical laboratories.

Asia-Pacific is expected to witness the fastest growth owing to improving healthcare infrastructure, increasing government investment in genomic medicine, expanding biotechnology industries, and rising adoption of molecular diagnostics. China, Japan, South Korea, India, and Australia continue strengthening regional sequencing capabilities.

Latin America and the Middle East & Africa are gradually expanding molecular diagnostic infrastructure through healthcare modernization, research collaborations, and growing investments in precision medicine.

Competitive Landscape

The market is characterized by continuous innovation in sequencing platforms, target enrichment technologies, bioinformatics, and companion diagnostics.

Major companies include Illumina, Thermo Fisher Scientific, QIAGEN, Roche, Agilent Technologies, Guardant Health, Natera, Exact Sciences, BGI Genomics, SOPHiA GENETICS, NeoGenomics Laboratories, Personalis, Adaptive Biotechnologies, Invitae, and GeneDx. Companies continue investing in AI-powered genomic interpretation, automated workflows, expanded sequencing panels, and strategic collaborations with healthcare providers and pharmaceutical organizations.

Future Outlook

The future of the targeted sequencing market will be driven by continued expansion of precision medicine, increasing use of companion diagnostics, growing demand for clinically actionable genomic information, and advances in AI-enabled variant interpretation. Technology providers are expected to deliver increasingly integrated sequencing workflows that combine target enrichment, sequencing, bioinformatics, and clinical reporting into streamlined diagnostic solutions, making targeted sequencing an essential component of routine molecular diagnostics.

Conclusion

The Global Targeted Sequencing Market is expected to experience strong growth through 2035, supported by expanding precision oncology programs, increasing biomarker-guided therapies, and continuous technological innovation in next-generation sequencing. Although implementation costs, bioinformatics complexity, and regulatory requirements remain important challenges, ongoing advances in sequencing technologies and genomic medicine are expected to create substantial opportunities for diagnostic manufacturers, biotechnology companies, healthcare providers, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global targeted sequencing market.
• Detailed evaluation of technologies, clinical applications, and emerging trends.
• Analysis of competitive strategies, technological innovation, and commercialization opportunities.
• Insights into precision medicine, companion diagnostics, and AI-powered genomic interpretation.
• Valuable resource for sequencing technology providers, biotechnology companies, healthcare organizations, pharmaceutical manufacturers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, precision medicine strategy, companion diagnostic development, partnership evaluation, commercialization planning, investment analysis, regulatory planning, and long-term business decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global targeted sequencing market by Product & Service, Technology, Application, End User, and Geography
• Evaluation of market dynamics, technology innovation, competitive landscape, regulatory environment, and future growth opportunities
• Assessment of amplicon-based sequencing, hybridization capture-based sequencing, oncology, hereditary disease testing, reproductive health testing, infectious disease testing, pharmacogenomics, AI-enabled variant interpretation, and companion diagnostics
• Analysis of instruments, consumables & reagents, sequencing services, bioinformatics & data analysis services, hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and emerging targeted sequencing technologies through 2035.